Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.0%

3 terminated out of 43 trials

Success Rate

89.3%

+2.8% vs benchmark

Late-Stage Pipeline

42%

18 trials in Phase 3/4

Results Transparency

8%

2 of 25 completed with results

Key Signals

2 with results89% success

Data Visualizations

Phase Distribution

36Total
Not Applicable (10)
Early P 1 (1)
P 1 (1)
P 2 (6)
P 3 (6)
P 4 (12)

Trial Status

Completed25
Unknown10
Terminated3
Withdrawn3
Recruiting2

Trial Success Rate

89.3%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (43)

Showing 20 of 20 trials
NCT07561801Not ApplicableCompleted

Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit

NCT04982419Phase 2Recruiting

Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial

NCT00639912Phase 4CompletedPrimary

Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction.

NCT06695429Not ApplicableRecruiting

Supplementation With Beetroot Juice to Prevent Contrast Associated Nephropathy During Hospitalization for Acute Coronary Syndrome Without ST Elevation

NCT01456013Phase 3UnknownPrimary

Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

NCT02516072Not ApplicableCompleted

Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy

NCT01999517Phase 4CompletedPrimary

Contrast Nephropathy and Nitrates

NCT01093131Phase 4WithdrawnPrimary

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

NCT00575419Phase 1TerminatedPrimary

Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure

NCT02669784Not ApplicableCompleted

Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study

NCT01402232UnknownPrimary

REduction of rIsk for Contrast Induced Nephropathy

NCT02106234Not ApplicableCompletedPrimary

A Maastricht Contrast-Induced Nephropathy Guidelines Study: CIN Prevention Guidelines: Appropriate & Cost-effective?

NCT03121053Phase 4Unknown

Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement

NCT00842868Completed

The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases

NCT00749827Phase 4WithdrawnPrimary

Renoprotective Effects of Fluid Prophylaxis Strategies for Contrast Induced Nephropathy (CIN)

NCT02650336CompletedPrimary

Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial

NCT00770796Phase 4CompletedPrimary

Statins for Prevention of Contrast Induced Nephropathy

NCT01144091Not ApplicableWithdrawnPrimary

Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography

NCT00312117Phase 3CompletedPrimary

Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

NCT01400295CompletedPrimary

PREdictive Value of COntrast voluMe to creatinINe Clearance Ratio

Scroll to load more

Research Network

Activity Timeline